Vesair Balloon Confirmatory Trial (VECTOR)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-11

Study Completion Date

2022-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the subject has provided informed consent and determination that all study entry criteria have been met.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Solace Stress Urinary inContinence Control Efficacy and Safety Study

NCT02210273

Stress Urinary Incontinence

COMPLETED NA

Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence

NCT04206085

Stress Urinary Incontinence

COMPLETED NA

VESPER: Stress Urinary Incontinence STUDY

NCT03996070

Female Stress Incontinence

COMPLETED NA

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648

Stress Urinary Incontinence (SUI)

RECRUITING NA

An Investigation With an Intra-vaginal Device for Stress Urinary Incontinence

NCT03186651

Stress Urinary Incontinence

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

Single-arm of subjects who receive treatment with Vesair Balloon

Group Type EXPERIMENTAL

Vesair Balloon

Intervention Type DEVICE

Treatment with Vesair Balloon for one year

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vesair Balloon

Treatment with Vesair Balloon for one year

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously treated with Vesair Balloon within the past 4 years
* Normal voiding function
* Has signed consent
* Willing to undergo cystoscopy
* Available for minimum of 12 months

Exclusion Criteria

* Last Menstrual Period within past 4 years
* Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
* History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
* Urinary incontinence of neurogenic etiology.
* Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
* Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
* Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
* Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
* History of recurrent (\>1) kidney stones, or one kidney stone within the past 5 years.
* History of an artificial urinary sphincter.
* Presence of gross hematuria and/or blood clots in the urine.
* History of interstitial or follicular cystitis or other painful bladder syndrome.
* Cystocele verified as Stage 3 or higher by PoP-Q Classification.
* Local genital skin infection.
* Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
* Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
* Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
* Non-ambulatory, bedridden or physically unable to complete test exercises.
* History of recent alcoholism or illicit drug abuse within the last year.
* Immunologically suppressed or immunocompromised.
* History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
* Uncontrolled diabetes (persistent A1C levels \>9 percent).
* History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
* Morbid obesity, defined as BMI ≥40.0.
* History of any autoimmune or connective tissue disease or disorder that could impact bladder function

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No